Cargando…

Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review

As coronavirus disease (COVID-19) vaccines continue to be administered, dermatologists play a critical role in recognizing and treating the cutaneous manifestations (CM) associated with the vaccines. Adverse cutaneous reactions of COVID-19 vaccines reported in the literature range from common urtica...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmood, Farhan, Cyr, Janelle, Li, Amy, Lipson, Jennifer, Pratt, Melanie, Beecker, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291118/
https://www.ncbi.nlm.nih.gov/pubmed/36789514
http://dx.doi.org/10.1177/12034754231156561
_version_ 1785062630245793792
author Mahmood, Farhan
Cyr, Janelle
Li, Amy
Lipson, Jennifer
Pratt, Melanie
Beecker, Jennifer
author_facet Mahmood, Farhan
Cyr, Janelle
Li, Amy
Lipson, Jennifer
Pratt, Melanie
Beecker, Jennifer
author_sort Mahmood, Farhan
collection PubMed
description As coronavirus disease (COVID-19) vaccines continue to be administered, dermatologists play a critical role in recognizing and treating the cutaneous manifestations (CM) associated with the vaccines. Adverse cutaneous reactions of COVID-19 vaccines reported in the literature range from common urticarial to rare vesiculobullous reactions. In this study, we performed a (1) scoping review to assess the occurrences of vesicular, papulovesicular, and bullous CMs of COVID-19 vaccines and their respective treatments, and (2) a narrative review discussing other common and uncommon CMs of COVID-19 vaccines. Thirty-six articles were included in the scoping review, and 66 articles in the narrative review. We found that vesicular, papulovesicular, and bullous lesions are infrequent, reported mostly after the first dose of Moderna or Pfizer vaccines. Eleven of the 36 studies reported vesicular reactions consistent with activation or reactivation of the herpes zoster virus. Most vesicular and bullous lesions were self-limited or treated with topical corticosteroids. Other CMs included injection-site, urticarial or morbilliform reactions, vasculitis, toxic epidermal necrolysis, and flaring of or new-onset skin diseases such as psoriasis. Treatments for CMs included topical or oral corticosteroids, antihistamines, or no treatment in self-limited cases. Although most CMs are benign and treatable, the data on the effect of systemic corticosteroids and immunosuppressive therapies on the immunogenicity of COVID-19 vaccines is limited. Some studies report reduced immunogenicity of the vaccines after high-dose corticosteroids use. Physicians may consult local guidelines where available when recommending COVID-19 vaccines to immunosuppressed patients, and when using corticosteroids to manage the CMs of COVID-19 vaccines.
format Online
Article
Text
id pubmed-10291118
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-102911182023-06-27 Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review Mahmood, Farhan Cyr, Janelle Li, Amy Lipson, Jennifer Pratt, Melanie Beecker, Jennifer J Cutan Med Surg Review Articles As coronavirus disease (COVID-19) vaccines continue to be administered, dermatologists play a critical role in recognizing and treating the cutaneous manifestations (CM) associated with the vaccines. Adverse cutaneous reactions of COVID-19 vaccines reported in the literature range from common urticarial to rare vesiculobullous reactions. In this study, we performed a (1) scoping review to assess the occurrences of vesicular, papulovesicular, and bullous CMs of COVID-19 vaccines and their respective treatments, and (2) a narrative review discussing other common and uncommon CMs of COVID-19 vaccines. Thirty-six articles were included in the scoping review, and 66 articles in the narrative review. We found that vesicular, papulovesicular, and bullous lesions are infrequent, reported mostly after the first dose of Moderna or Pfizer vaccines. Eleven of the 36 studies reported vesicular reactions consistent with activation or reactivation of the herpes zoster virus. Most vesicular and bullous lesions were self-limited or treated with topical corticosteroids. Other CMs included injection-site, urticarial or morbilliform reactions, vasculitis, toxic epidermal necrolysis, and flaring of or new-onset skin diseases such as psoriasis. Treatments for CMs included topical or oral corticosteroids, antihistamines, or no treatment in self-limited cases. Although most CMs are benign and treatable, the data on the effect of systemic corticosteroids and immunosuppressive therapies on the immunogenicity of COVID-19 vaccines is limited. Some studies report reduced immunogenicity of the vaccines after high-dose corticosteroids use. Physicians may consult local guidelines where available when recommending COVID-19 vaccines to immunosuppressed patients, and when using corticosteroids to manage the CMs of COVID-19 vaccines. SAGE Publications 2023-02-15 /pmc/articles/PMC10291118/ /pubmed/36789514 http://dx.doi.org/10.1177/12034754231156561 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review Articles
Mahmood, Farhan
Cyr, Janelle
Li, Amy
Lipson, Jennifer
Pratt, Melanie
Beecker, Jennifer
Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review
title Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review
title_full Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review
title_fullStr Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review
title_full_unstemmed Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review
title_short Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review
title_sort vesiculobullous and other cutaneous manifestations of covid-19 vaccines: a scoping and narrative review
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291118/
https://www.ncbi.nlm.nih.gov/pubmed/36789514
http://dx.doi.org/10.1177/12034754231156561
work_keys_str_mv AT mahmoodfarhan vesiculobullousandothercutaneousmanifestationsofcovid19vaccinesascopingandnarrativereview
AT cyrjanelle vesiculobullousandothercutaneousmanifestationsofcovid19vaccinesascopingandnarrativereview
AT liamy vesiculobullousandothercutaneousmanifestationsofcovid19vaccinesascopingandnarrativereview
AT lipsonjennifer vesiculobullousandothercutaneousmanifestationsofcovid19vaccinesascopingandnarrativereview
AT prattmelanie vesiculobullousandothercutaneousmanifestationsofcovid19vaccinesascopingandnarrativereview
AT beeckerjennifer vesiculobullousandothercutaneousmanifestationsofcovid19vaccinesascopingandnarrativereview